RT Journal Article
SR Electronic
T1 Early medical abortion by telemedicine in the United Kingdom: A cost-effectiveness analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.26.21252518
DO 10.1101/2021.02.26.21252518
A1 James E Hawkins
A1 Anna Glasier
A1 Stephen Hall
A1 Lesley Regan
A1 on behalf of the RCOG Telemedicine cost-effectiveness working group
A1 Homerton University Hospital Foundation Trust
A1 University Hospitals Bristol NHS Foundation Trust
A1 Aneurin Bevan University Health Board
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252518.abstract
AB Objective To determine the potential cost savings resulting from the introduction of routine early medical abortion at home by telemedicine in the United Kingdom.Design A cost-effectiveness analysis Setting: United KingdomPopulation Women in 2020 undergoing early medical abortion provided by three independent abortion providers and two NHS abortion clinics.Methods Computation of the costs of each abortion procedure and of managing failed or incomplete abortion and haemorrhage requiring blood transfusion.Outcome measures Cost savingsResults Overall estimated cost savings are £15.80 per abortion undertaken by independent abortion providers representing a saving to the NHS of over £3 million per year. Limited data from NHS services resulted in an estimated average saving of £188.84 per abortion.Conclusions Were telemedicine EMA to become routine, an increase in the number of women eligible for medical rather than surgical abortion, and a reduction in adverse events resulting from earlier abortion could result in significant cost-savings.Tweetable Abstract Early medical abortion at home using telemedicine could save the NHS £3 million per yearCompeting Interest StatementThe authors have declared no competing interest.Funding StatementFunding from CHARM Foundation UKAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required: Evaluative cost-effectiveness analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData openly available in a public repository that issues datasets with DOIs. Other data available on request. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.16668